Sage Journals: Discover world-class research

Retricted access

Research article

First published 2014-10

Formulary Selection Criteria for Biosimilars: Considerations for US Health-System Pharmacists

Niesha Griffith, Ali McBride, James G. Stevenson [...]

Hospital Pharmacy

Retricted access

Other

First published 2011-3

Requirements for Biosimilars and Interchangeable Biological Drugs in the United States—in Plain Language

Suzanne M. Sensabaugh

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 2007-4

Biological Generics: A Business Case

Suzanne M. Sensabaugh

Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector

Retricted access

Review article

First published 2021-8

Can biosimilar products be interchangeable? Pharmaceutical perspective in the implementation of biosimilars in oncology

José Cleberson Santos Soares, Iago Dillion Lima Cavalcanti, Juliana Lúcia de Albuquerque Vasconcelos

Journal of Oncology Pharmacy Practice

Retricted access

Research article

First published 2005-1

Scientific Issues for Biogenerics/Biosimilars

Robert I. Roth, Nicholas M. Fleischer

Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector

Retricted access

Research article

First published 2010-8

Regulatory basis of biosimilar medicinal products: Need for harmonization

B. Calvo, L. Zuñiga

Pharmaceuticals Policy and Law

Retricted access

Research article

First published 2005-1

The EU Regulatory Environment for ‘Biosimilars’: Today's Picture and Future Prospects

Nicolas Rossignol

Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector

Retricted access

Research article

First published 2009-5

A Follow-On Biological Drug is not a Biogeneric: Lessons from Omnitrope and Valtropin

Robert I. Roth, Nicholas M. Fleischer

Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector

Free access

Other

First published 2009-2

How the European Union reviews and approves ‘follow-on biologics’ or biosimilar products

Nicolas Rossignol

International Journal of Risk & Safety in Medicine

Retricted access

Research article

First published 2008-9

Biosimilars: A Regulatory Review

Pia Furlani

Therapeutic Innovation & Regulatory Science

Search results